Association of lipoprotein (a) and in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

References

• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: A report from the American heart association. Circulation. 2020;141(9):e139–e596.
   PubMed Web of Science ®Google Scholar
• Chinese guidelines for the prevention of cardiovascular diseases(2017). Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46(1):10–25.
   PubMedGoogle Scholar
• Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American college of cardiology foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. J Am Coll Cardiol. 2011;58(23):2432–2446.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–827. .
   PubMed Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(SupplC):C2–c12.
   PubMedGoogle Scholar
• Nichols GA, Philip S, Reynolds K, et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21(2):366–371.
   PubMed Web of Science ®Google Scholar
• Lieb W, Enserro DM, Larson MG, et al. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart. 2018;5(1):e000722.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504. .
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435. .
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Jama. 2005;294(19):2437–2445. .
   PubMed Web of Science ®Google Scholar
• Cai A, Li L, Zhang Y, et al. Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551–559.
   PubMedGoogle Scholar
• Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524–533. .
   PubMed Web of Science ®Google Scholar
• Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589–2596.
   PubMed Web of Science ®Google Scholar
• Cai A, Li L, Zhang Y, et al. Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis Markers. 2013;35(6):857–862. .
   PubMedGoogle Scholar
• Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953–1975.
   PubMed Web of Science ®Google Scholar
• Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–1320. .
   PubMed Web of Science ®Google Scholar
• Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–627. .
   PubMed Web of Science ®Google Scholar
• Gazzola K, Reeskamp L, van den Born BJ. Ethnicity, lipids and cardiovascular disease. Curr Opin Lipidol. 2017;28(3):225–230.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492. .
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Aday AW, Rose LM, et al. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. 2018;138(2):141–149.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. .
   PubMed Web of Science ®Google Scholar
• Steffen BT, Duprez D, Bertoni AG, et al. Lp(a) [Lipoprotein(a)]-related risk of heart failure is evident in whites but not in other racial/ethnic groups. Arterioscler Thromb Vasc Biol. 2018;38(10):2498–2504.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255. .
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):2490–2498. .
   PubMed Web of Science ®Google Scholar
• Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745–757.
   PubMed Web of Science ®Google Scholar
• Cesaro A, Schiavo A, Moscarella E, et al. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med (Hagerstown). 2020. DOI:10.2459/JCM.0000000000001077.
   Google Scholar
• Lima LM, Carvalho M, Loures-Vale AA, et al. Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography. Arq Bras Cardiol. 2006;87(3):260–266. .
   PubMedGoogle Scholar
• You XD, Jin JL, Zhang H, et al. Lipoprotein(a) as a marker for predicting coronary collateral circulation in patients with acute myocardial infarction. Per Med. 2020;17(1):67–78. .
   PubMed Web of Science ®Google Scholar
• Kamitani T, Taniguchi T, Miyai N, et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ J. 2005;69(6):644–649.
   PubMed Web of Science ®Google Scholar
• Qin SY, Liu J, Jiang HX, et al. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis. 2013;227(2):360–366.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Fimiani F, Di Maio M, et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med. 2019;14(4):621–625. .
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail. 2016;4(1):78–87.
   PubMed Web of Science ®Google Scholar